These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

579 related items for PubMed ID: 10757623

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG.
    Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
    [Abstract] [Full Text] [Related]

  • 3. A one-year trial to assess the value of orlistat in the management of obesity.
    James WP, Avenell A, Broom J, Whitehead J.
    Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S24-30. PubMed ID: 9225173
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.
    Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J.
    Diabetes Care; 1998 Aug; 21(8):1288-94. PubMed ID: 9702435
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D, Ivković-Lazar T, Dragojević R, Jorga J, Stokić E, Hajduković Z.
    Med Pregl; 1999 Aug; 52(9-10):323-33. PubMed ID: 10624380
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
    Hill JO, Hauptman J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, Zavoral JH, Aronne LJ.
    Am J Clin Nutr; 1999 Jun; 69(6):1108-16. PubMed ID: 10357727
    [Abstract] [Full Text] [Related]

  • 16. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [Abstract] [Full Text] [Related]

  • 17. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns.
    Karhunen L, Franssila-Kallunki A, Rissanen P, Valve R, Kolehmainen M, Rissanen A, Uusitupa M.
    Int J Obes Relat Metab Disord; 2000 Dec; 24(12):1567-72. PubMed ID: 11126207
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
    Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P.
    Diabetes Care; 2002 Jun; 25(6):1033-41. PubMed ID: 12032111
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.